Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:670-676

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v44,pe2)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuo, J. J.
Right arrow Articles by Hall, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuo, J. J.
Right arrow Articles by Hall, J. E.
Related Collections
Right arrow Obesity
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies
Right arrow Autonomic, reflex, and neurohumoral control of circulation
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2001;37:670.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Inhibition of NO Synthesis Enhances Chronic Cardiovascular and Renal Actions of Leptin

Jay J. Kuo; Oscar B. Jones; John E. Hall

From the Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson.

Correspondence to John E. Hall, PhD, Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216-4505. E-mail jehall{at}physiology.umsmed.edu

Acute studies suggest that leptin has pressor and depressor actions, including stimulation of sympathetic activity as well as increased release of NO from the vascular endothelium. The goal of this study was to examine the role of NO in modulating the chronic blood pressure, heart rate, and renal responses to hyperleptinemia, comparable to that found in obesity-induced hypertension. Male Sprague-Dawley rats were implanted with arterial and venous catheters, and mean arterial pressure and heart rate were monitored continuously 24 h/d. After a 4-day control period, the rats were infused with isotonic saline vehicle (n=6) or NG-nitro-L-arginine methyl ester (L-NAME, 10 µg/kg per minute; n=9) to inhibit NO synthesis for 7 days. After 7 days of vehicle or L-NAME administration, leptin was infused intravenously for 7 days at a rate of 0.5 µg/kg per minute, followed by a leptin infusion at 1.0 µg/kg per minute for 7 days, along with vehicle or L-NAME. A 21-day infusion of L-NAME alone (n=6) served as a control for the L-NAME+leptin rats. Although the low dose of leptin alone did not significantly elevate arterial pressure, it raised the heart rate by 18±3 bpm. The higher leptin infusion rate raised arterial pressure from 96±3 to 104±3 mm Hg but did not increase the heart rate further. L-NAME+leptin increased arterial pressure by 40±6 mm Hg and heart rate by 79±19 bpm compared with pretreatment levels. In control L-NAME rats, mean arterial pressure increased by 31±4 mm Hg, whereas the heart rate was not altered significantly compared with pretreatment levels. Neither chronic leptin infusion alone nor L-NAME alone altered the glomerular filtration rate or renal plasma flow significantly, but L-NAME+leptin reduced glomerular filtration rate by 27±11% and renal plasma flow by 47±9%. These results indicate that impaired NO synthesis mildly enhances the chronic renal hemodynamic and hypertensive effects of leptin but markedly amplifies the tachycardia caused by hyperleptinemia.


Key Words: hypertension • blood pressure • heart rate • nitric oxide • diet




This article has been cited by other articles:


Home page
HypertensionHome page
A. A. da Silva, J. M. do Carmo, B. Kanyicska, J. Dubinion, E. Brandon, and J. E. Hall
Endogenous Melanocortin System Activity Contributes to the Elevated Arterial Pressure in Spontaneously Hypertensive Rats
Hypertension, April 1, 2008; 51(4): 884 - 890.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Yang and L. A. Barouch
Leptin Signaling and Obesity: Cardiovascular Consequences
Circ. Res., September 14, 2007; 101(6): 545 - 559.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. Knudson, U. D. Dincer, G. M. Dick, H. Shibata, R. Akahane, M. Saito, and J. D. Tune
Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1038 - H1046.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. W. Kurtz, K. A. Griffin, A. K. Bidani, R. L. Davisson, and J. E. Hall
Recommendations for Blood Pressure Measurement in Humans and Experimental Animals: Part 2: Blood Pressure Measurement in Experimental Animals. A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research
Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): e22 - e33.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. W. Kurtz, K. A. Griffin, A. K. Bidani, R. L. Davisson, and J. E. Hall
Recommendations for Blood Pressure Measurement in Humans and Experimental Animals: Part 2: Blood Pressure Measurement in Experimental Animals: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research
Hypertension, February 1, 2005; 45(2): 299 - 310.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. J. Kuo, A. A. da Silva, L. S. Tallam, and J. E. Hall
Role of Adrenergic Activity in Pressor Responses to Chronic Melanocortin Receptor Activation
Hypertension, February 1, 2004; 43(2): 370 - 375.
[Abstract] [Full Text] [PDF]


Home page
Recent Prog Horm ResHome page
A. Aneja, F. El-Atat, S. I. McFarlane, and J. R. Sowers
Hypertension and Obesity
Recent Prog. Horm. Res., January 1, 2004; 59(1): 169 - 205.
[Abstract] [Full Text]


Home page
Recent Prog Horm ResHome page
K. Rahmouni and W. G. Haynes
Leptin and the Cardiovascular System
Recent Prog. Horm. Res., January 1, 2004; 59(1): 225 - 244.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. J. Kuo, O. B. Jones, and J. E. Hall
Chronic cardiovascular and renal actions of leptin during hyperinsulinemia
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1037 - R1042.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. Shirasaka, M. Takasaki, and H. Kannan
Cardiovascular effects of leptin and orexins
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2003; 284(3): R639 - R651.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. J. Kuo, A. A. Silva, and J. E. Hall
Hypothalamic Melanocortin Receptors and Chronic Regulation of Arterial Pressure and Renal Function
Hypertension, March 1, 2003; 41(3): 768 - 774.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Carlyle, O. B. Jones, J. J. Kuo, and J. E. Hall
Chronic Cardiovascular and Renal Actions of Leptin: Role of Adrenergic Activity
Hypertension, February 1, 2002; 39(2): 496 - 501.
[Abstract] [Full Text] [PDF]